Additional U.S. Patents for Lead Cancer Drug Candidate Strengthen Critical Outcome's Investment Proposition
COTI-2 continues to increase in value with four U.S. patents granted and several more pending
(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 04/26/13 -- Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) is pleased to announce that the United States ("U.S.") Patent and Trademark Office has recently granted two patents for the Company's lead oncology asset, COTI-2. These build on two previously granted patents in providing further protection and added value to the compound.
"These additional patents provide further support for developing COTI-2 as an exciting new cancer therapy," said Dr. Wayne Danter, President and CEO of COTI. "The continued strengthening of our patent position is consistent with our extensive pre-clinical evaluation of the drug. We believe it is only a matter of time before the world recognizes the importance of COTI-2 to cancer treatment and a partner comes forward to take this drug to the clinic."
Newly issued patents
U.S. Patent 8,367,675 covers methods of treatment of various cancers using the family of compounds to which COTI-2 belongs. This patent provides additional support for the clinical use of the broad family of compounds.
U.S. Patent 8,420,643 covers a subset of the COTI-2 family in order to provide additional support for the compounds found most useful in pre-clinical testing.
About Critical Outcome Technologies Inc.
COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit .
Follow (at)CriticalOutcome on Twitter at .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 1220726
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LONDON, ONTARIO
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 105 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Additional U.S. Patents for Lead Cancer Drug Candidate Strengthen Critical Outcome's Investment Proposition
"
steht unter der journalistisch-redaktionellen Verantwortung von
Critical Outcome Technologies Inc. (COTI) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
